Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | MOUNTAINEER results: trastuzumab and tucatinib for HER2+ mCRC

John Strickler • 27 Sep 2019
ESMO 2019
Colorectal Cancer Gastrointestinal Cancer Trastuzumab Tucatinib
MOUNTAINEER

John Strickler, MD, Duke Cancer Center, Durham, NC, discusses the initial results of the MOUNTAINEER trial (NCT03043313). This Phase II trial studies how the HER2 inhibitor tucatinib works in combination with trastuzumab in treating patients with HER2-positive metastatic colorectal cancer (mCRC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from John Strickler

1:25
Real-world treatment patterns for HER2-amplified colorectal cancer
John Strickler • 21 Oct 2023
0:44
Using ctDNA to identify mutations in colorectal cancer
John Strickler • 21 Oct 2023
0:58
MOUNTAINEER: clinical relevance of genomic profiling for tucatinib + trastuzumab treatment in mCRC
John Strickler • 21 Oct 2023
2:28
MOUNTAINEER: impact of genomic alterations on tucatinib plus trastuzumab activity in mCRC
John Strickler • 21 Oct 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals